Astal Laboratories has informed that Board of Directors of the Company in its meeting held on today i.e. Monday 29th June, 2026 at the corporate office of the company, House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032, which commenced at 10:00 AM, has taken the following decisions: Authorised Sudheer Karna Kankanala, Whole-time Director of the Company, to initiate discussions, evaluate opportunities and negotiate the proposed acquisition of one or more USFDA and/or EU-GMP and/or WHO/GMP compliant/approved pharmaceutical manufacturing unit(s) in India with a view to expanding the Company's manufacturing capacity to meet rising order volumes and strengthen its presence in the global market; Authorised Balayogiswara Rao Peddinti, Chief Financial officer of the Company to engage in discussions and negotiations with prospective investors, financial institutions and other funding sources for raising an aggregate amount of up to Rs.300 Crore (Rupees Three Hundred Crore only) through any one or a combination of convertible instruments, including Compulsorily Convertible Debentures (CCDs) and/or Compulsorily Convertible Preference Shares (CCPS), and/or non-convertible instruments, including Non-Convertible Debentures (NCDs), by way of private placement and/or such other permissible modes as may be considered appropriate, subject to applicable statutory, regulatory and shareholders' approvals.
The above information is a part of company’s filings submitted to BSE.
